Is Biopharma Poised For Bigger Deals In 2022?
Source: Life Science Leader
By Benet O'Reilly
After total deal value in the biopharma industry dipped to $108 billion in 2021 — its second-lowest level in eight years — it's natural to speculate whether that trend will continue in 2022. Will we see a resumption of transformative dealmaking? Or will we continue to see a high level of lower-value deals featuring bolt-on transactions, partnerships, and alliances?
VIEW THE MAGAZINE ARTICLE!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more